[email protected]

01252 375362

01252 375362

  • About Us
    • About Pharmacy Consulting
    • Our Team
    • Work With Us
    • Testimonials
  • Consultancy
    • For Pharmaceutical Wholesalers
    • For Pharmacies
    • Care Quality Commission – CQC
    • Pharmaceutical Manufacturers
    • Medical Devices Consultancy and Training
  • Academy Training
  • Bespoke Training
  • Making Pharmaceuticals Show
  • Our CPD
    • Blog
    • Editorial Items
    • Social Media
  • Contact Us
MHRA Response to contaminated paediatric medicines

MHRA Response to contaminated paediatric medicines

by Amelia Holmes | Oct 27, 2022 | Blog, GDP/RP, Good Distribution Practice - GDP, MHRA, Training

On the 7th of October The Medicines and Healthcare products Regulatory Agency (MHRA) released a response to contaminated paediatric medicines identified by the WHO region of Africa.

The Canada – United Kingdom Trade Continuity Agreement (CUK TCA) Protocol

The Canada – United Kingdom Trade Continuity Agreement (CUK TCA) Protocol

by Amelia Holmes | Sep 26, 2022 | Blog

The Canada – United Kingdom Trade Continuity Agreement (CUK TCA) was entered into force on the 1st of April 2021.

Defective Medicinal Products and Recall Management Guidance

Defective Medicinal Products and Recall Management Guidance

by Amelia Holmes | Aug 5, 2022 | Blog, MHRA

The main concerns with regard to possible defects of medicinal products and the substances used in their manufacture or packaging.

Import Licensed Human Medicine(s) to the United Kingdom (UK) – Guidance

Import Licensed Human Medicine(s) to the United Kingdom (UK) – Guidance

by Amelia Holmes | Jul 13, 2022 | Blog, MHRA, WDA(H), WDA(H)

Import Licensed Human Medicine – Prior to importation of a licensed medicine applications for the relevant Licence(s) must be completed and submitted which may include one or more of the following:

Import Unlicensed Human Medicine(s) to the United Kingdom (UK) – guidance

Import Unlicensed Human Medicine(s) to the United Kingdom (UK) – guidance

by Amelia Holmes | Jul 13, 2022 | Blog, Good Distribution Practice - GDP, MHRA, WDA(H)

An Introduced Product is an unlicensed medicine which can be imported from a country other than an approved country for import to be exported to a country other than an approved country for import, or if imported from a non-EEA country into Northern Ireland for export back to a country outside the EEA.

« Older Entries
Next Entries »

Recent Posts

  • RP Refresher Training
  • The MHRA’s Guide to Defective Medicinal Products – Part 2
  • The MHRA’s Guide to Defective Medicinal Products – Part 1: Overview

Upcoming Courses

  • Understanding GPhC Guidance for Online Pharmacies – Online Training on 16 March 2026
  • GDP/RP Cogent Gold Standard Online Training on 17 March 2026
  • GDP/RP Cogent Gold Standard WEEKEND Training on 20 March 2026 9:30 am
  • Introduction to Good Distribution Practice Online Training on 20 March 2026 10:00 am
  • RP Forum – tbc on 7 April 2026 10:00 am

MHRA Alerts & Recalls

Class 2 Medicines Recall: Rokshaw Limited Trading as Curaleaf Laboratories, Curaleaf Oil [FS] 10mg/ml THC, 10mg/ml CBD (30ml), EL(26)A/13
12 March 2026
Class 3 Medicines Recall: Bayer Plc, Various Products, EL(26)A/12
12 March 2026
Field Safety Notices: 02 to 06 March 2026
9 March 2026
Class 2 Medicines Recall: Crescent Pharma Limited, Ramipril 5mg capsules, EL(26)A/11
6 March 2026

Get In Touch

Address:
Wellesley House
10 Eelmoor Road
Farnborough
Hampshire
GU14 7QN

Phone: 01252 375362
Email: [email protected]
  • Terms and Conditions
  • Privacy Policy

Designed by Four Lakes

  • Follow
  • Follow
  • Follow
  • Follow